source
- FDA approves Revolution Medicines' daraxonrasib for second-line pancreatic cancerThe U.S. Food and Drug Administration announced approval of Revolution Medicines' drug daraxonrasib for patients with pancreatic cancer who have already received prior therapy. The approval marks…
- Biohaven secures up to $795 million partnership with SK Biopharma for global epilepsy drug rightsBiohaven announced a commercial partnership for its late-stage epilepsy program. South Korea-based SK Biopharma has agreed to pay up to $795 million for worldwide rights to the company's Kv7 ion ch…